Genprex, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Genprex, Inc. on July 13, 2026. The filing primarily addresses a material modification to the rights of security holders via a reverse stock split and provides updates on the company's clinical trial programs in oncology. The company is currently listed on The Nasdaq Capital Market under the symbol GNPX.
Key Financial and Operational Metrics
The filing does not provide specific revenue, profit, cash flow, or debt figures for the reporting period. Key operational metrics include:
- Share Count: 11,108,577 shares of Common Stock outstanding as of July 13, 2026.
- Post-Split Estimate: Approximately 504,936 shares outstanding immediately following the reverse stock split (prior to rounding).
- Stock Split Ratio: One-for-twenty-two (1:22).
- Effective Date: July 16, 2026, at 12:01 a.m. Eastern Time.
- CUSIP Change: New CUSIP number will be 372446-401.
Material Changes and Corporate Actions
The most significant material change is the implementation of a 1:22 reverse stock split, approved by the Board of Directors on July 2, 2026, and authorized by stockholders at the annual meeting on June 18, 2026. This action is intended to address non-compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The company received a delisting notice from Nasdaq on June 10, 2026, and has requested a hearing before a Nasdaq Hearings Panel to stay the delisting action.
Outlook, Management Commentary, and Risks
Clinical Program Updates:
- Acclaim-1 (NSCLC): The Phase 1/2 trial is currently in the Phase 2a expansion portion. The study combines REQORSA with AstraZeneca's Tagrisso. Phase 1 data showed prolonged progression-free survival in some patients, with one patient achieving a partial response and remaining on treatment for approximately 46 months. The trial has received FDA Fast Track Designation. Biomarker research (TROP-2 and PTEN) suggests potential for targeted patient selection.
- Acclaim-3 (ES-SCLC): The Phase 1/2 trial is in the Phase 2 expansion portion, combining REQORSA with Genentech's Tecentriq. The company expects to enroll the first 25 patients for interim analysis by the end of 2026, with the analysis expected in the first half of 2027. The trial holds FDA Fast Track and Orphan Drug Designations.
Risks and Contingencies:
- Delisting Risk: There is no assurance that the reverse stock split will result in regaining compliance with the $1.00 bid price requirement or that the Nasdaq Hearings Panel will grant continued listing.
- Market Impact: The reverse stock split could negatively affect the stock price, reduce liquidity due to fewer shares outstanding, and result in a lower total market capitalization.
- Forward-Looking Statements: The filing includes standard disclaimers regarding the uncertainty of clinical timelines, regulatory approvals, and the success of the reverse stock split in maintaining Nasdaq listing.
Investor Verification Checklist
- Verify the effective date and trading status of the 1:22 reverse stock split on July 16, 2026.
- Monitor the outcome of the Nasdaq Hearings Panel regarding the company's delisting notice.
- Confirm the post-split share price and whether it sustains the $1.00 minimum bid price for 10 consecutive business days.
- Review the investor presentation (Exhibit 99.1) for detailed updates on the Acclaim-1 and Acclaim-3 clinical trial enrollment and data readouts.
- Check for any subsequent filings regarding the adjustment of outstanding stock options and warrants.